Overview

INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Status:
Recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
In this study, the investigators propose to combine INCMGA00012 with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM). The investigators hypothesize that this combination provides a powerful synergy between RT and immune modulators to produce more robust anti-tumor immune response, induce tumor regression and improve overall survival.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Incyte Corporation
Treatments:
Antibodies, Monoclonal
Bevacizumab